Abivax SA - American Depositary Shares (ABVX)

Abivax Presents First Half 2025 Financial Results

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis  

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease